Optimization of Rh blood group antigen precision transfusion strategy across multiple hospital campuses by PDCA circle
10.13303/j.cjbt.issn.1004-549x.2025.01.018
- VernacularTitle:PDCA框架下多院区Rh血型抗原精准输注策略优化
- Author:
Qiming YING
1
;
Luyan CHEN
1
;
Kedi DONG
1
;
Yiwen HE
1
;
Yating ZHAN
1
;
Yexiaoqing YANG
1
;
Feng ZHAO
1
;
Dingfeng LYU
1
Author Information
1. Department of Blood Transfusion, The First Affiliated Hospital of Ningbo University, Ningbo 315010, China
- Publication Type:Journal Article
- Keywords:
PDCA cycle;
Rh blood group system;
antigen;
phenotype;
transfusion compatibility rate
- From:
Chinese Journal of Blood Transfusion
2025;38(1):106-111
- CountryChina
- Language:Chinese
-
Abstract:
[Objective] To explore the effectiveness of applying the PDCA (Plan-Do-Check-Act) cycle to enhance the compatibility rate of five Rh blood group antigen phenotypes between donors and recipients across multiple hospital campuses. [Methods] Clinical blood transfusion data from May to July 2022 were selected. Specific improvement measures were formulated based on the survey results, and the PDCA cycle management model was implemented from August 2022. The post-intervention phase spanned from August 2022 to October 2023. The Rh phenotype compatibility rate, the detection rate of Rh system antibodies, and the proportion of Rh system antibodies among unexpected antibodies were compared between the pre-intervention phase (May to July 2022) and the post-intervention phase. [Results] After the continuous improvement with the PDCA cycle, the compatibility rate for the five Rh blood group antigen phenotypes between donors and recipients from August to October 2023 reached 81.90%, significantly higher than the 70.54% recorded during the pre-intervention phase (May to July 2022, P<0.01), and displayed a quarterly upward trend (β=0.028, P<0.05). The detection rate of Rh blood group system antibodies (β=-9.839×10-5, P<0.05) and its proportion among all detected antibodies (β=-0.022, P<0.05) showed a quarterly decreasing trend, both demonstrating a negative correlation with the enhanced compatibility rate (r values of -0.981 and -0.911, respectively; P<0.05). [Conclusion] The implementation of targeted measures through the PDCA cycle can effectively increase the compatibility rate of five Rh blood group antigen phenotypes between donors and recipients, reduce the occurrence of unexpected Rh blood group antibodies, thereby lowering the risk of transfusion and enhancing the quality and safety of medical care.
